

New spinosin derivatives from the seeds of *Ziziphus mauritiana*

Bin WANG,^{a,b} Hong-Tao ZHU,^a Dong WANG,^a Chong-Ren YANG,^a Min XU,^{a,*} and Ying-Jun ZHANG^{a,*}

^aState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China

^bUniversity of Chinese Academy of Sciences, Beijing 100049, China

Received 28 March 2013; Accepted 16 April 2013

© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract: Three new acylated flavonoid C-glycosides, 6'''-(–)-phaseoylspinosin (**1**), 6'''-(3''',4''',5'''-trimethoxyl)-(E)-cinnamoylspinosin (**2**), and 6'''-(4'''-O-β-D-gluco-pyranosyl)-benzoylspinosin (**3**), were isolated from the seeds of *Ziziphus mauritiana* (Rhamnaceae). A further 19 known compounds including eight spinosin analogues (**4–11**) were also isolated. Their structures were elucidated by means of spectroscopic analysis and chemical method. Among spinosin derivatives **1**, **2**, **4**, **7**, **8**, and triterpenoid saponin **14**, jujuboside A (**14**) displayed moderate acetylcholinesterase (AChE) inhibitory activity with an inhibition value of 46.2% at a concentration of 1 μM.

Keywords: *Ziziphus mauritiana*, Rhamnaceae, seeds, spinosin derivatives, jujuboside A, acetylcholinesterase inhibitory

Introduction

The genus *Ziziphus* (Rhamnaceae), comprises of approximately 170 species and 12 variants, and is distributed in the warm-temperate and subtropical regions throughout the world. Thirteen of which are distributed in the southern and eastern China. Most *Ziziphus* species are important sources for their edible fruits and medicinal uses.^{1–3} In the Chinese Pharmacopoeia, the dry seeds of *Z. jujuba* Mill var. *spinosa* (Bunge) Hu ex H. F. Chou, commonly named as Semen Ziziphi Spinosae (“Suan-Zao-Ren”), have been used traditionally to tranquilize and relax the mind, soothing nerves (anxiolytic), and reducing sweating (anti-hydronic) effect. Flavonoids, saponins and alkaloids were previously reported as isolated from the seeds of *Z. jujuba*.^{4–6}

On the other hand, *Z. mauritiana* Lam., an evergreen shrub up to 15 m height, is distributed in the southern China. It is also widely growing throughout low-latitudes of Asia, Africa and Australia.^{1,2} The dry seeds have been used as a substitute of “Suan-Zao-Ren” (seeds of *Z. jujuba* var. *spinosa*) by local people in Yunnan province of China. Cyclopeptide,^{1,7–12} triterpenes,¹ flavones,¹ steroids,^{1,13} and aliphatic compounds^{1,14} have previously been identified from the roots, barks and leaves of *Z. mauritiana*. Interestingly, some of these compounds showed antitumor, anti-HIV,^{15,16} anti-plasmodial and anti-mycobacterial activities.¹² However, no chemical study was reported on the seeds. As a part of our continuing study of the chief phytotherapeutic components of traditional Chinese medicines (TCM),^{17–19} the phytochemical investigation on the




Figure 1. Chemical structures of flavonoids **1–3**

seeds of *Z. mauritiana* was carried on. This led to the isolation of 11 spinosin derivatives (**1–11**), along with 11 other known compounds (**12–22**). Compounds **1–3** are new acylated flavonoid C-glycosides. The acetylcholinesterase (AChE) inhibitory activities of the major isolates were tested, using tacrine as the positive control.

Results and Discussion

The defatted MeOH extract of the air-dried seeds of *Z. mauritiana* was applied to column chromatography (CC) over Diaion HP20SS, Sephadex LH-20, Chromatorex ODS, Toyopearl HW40C, silica gel, MCI-gel CHP20P, and RP-18, finally to semi-preparative HPLC, to give three new compounds (**1–3**) and 19 known ones. The known compounds (see Electronic Supplementary Material) were determined to

*To whom correspondence should be addressed. E-mail: zhangyj@mail.kib.ac.cn (Y.J. Zhang); xumin@mail.kib.ac.cn (M. Xu)

Table 1. ^1H (600 MHz) and ^{13}C (150 MHz) NMR spectroscopic data of compound **1** (DMSO- d_6 ; 313 K; δ in ppm)


pos.	δ_{H} (J, Hz)	δ_{C}	pos.	δ_{H} (J, Hz)	δ_{C}
2		164.10/163.90, C	2 ^{'''}	2.84 (t, 8.8)	74.49/74.43, CH
3	6.79/6.72 (s)	103.12/103.03, CH	3 ^{'''}	3.06 (m)	76.25/76.19, CH
4		182.23/181.95, C	4 ^{'''}	2.94 (t, 8.9)	69.12/69.09, CH
5		160.69/159.57, C	5 ^{'''}	2.86 (m)	73.51/73.44, CH
6		108.89/108.81, C	6 ^{'''}	3.87 ^a /3.62 (m)	62.42/61.65, CH ₂
7		165.14/163.67, C	1 ^{'''}		81.40/81.37, C
8	6.77/6.72 (s)	90.65/90.10, CH	2 ^{'''}		48.66/48.28, C
9		157.03/156.92, C	3 ^{'''}	H _{β} 2.61 (m)/H _{α} 2.27 (m)	52.00/51.96, CH ₂
10		104.48/104.08, C	4 ^{'''}		208.37/208.35, C
1 [']		121.14/121.10, C	5 ^{'''}	H _{β} 2.76 (m)/H _{α} 2.30 (m)	53.00, CH ₂
2 ['] ,6 [']	7.91/7.91 (d, 8.8)	128.52/128.49, CH	6 ^{'''}		86.04/86.01, C
3 ['] ,5 [']	6.91/6.90 (d, 8.8)	115.93/115.92, CH	7 ^{'''}	6.40/6.39 (d, 15.7)	134.22/134.14, CH
4 [']		161.23, C	8 ^{'''}	7.89/7.81 (d, 15.7)	130.35/130.31, CH
7-OMe	3.89/3.87 (s) ^a	56.45/56.16, CH ₃	9 ^{'''}		150.60/150.52, C
1 ^{''}	4.70/4.68 (d, 10.1)	71.07/70.76, CH	10 ^{'''}	1.91/1.87 (s)	20.72/20.70, CH ₃
2 ^{''}	4.46 (t, 9.4)/4.24 ^b	80.89/79.62, CH	11 ^{'''}	3.80/3.53 (m)	76.66, CH ₂
3 ^{''}	3.46/3.44 ^c	78.70/78.46, CH	12 ^{'''}	0.88/0.87 (s)	15.35/15.28, CH ₃
4 ^{''}	3.17 ^c	70.48/70.41, CH	13 ^{'''}	1.06/1.03 (s)	19.15/19.11, CH ₃
5 ^{''}	3.17 ^c	81.82/81.60, CH	14 ^{'''}	5.50 (s)	116.72/116.66, CH
6 ^{''}	3.39 ^c /3.69 (m)	61.55/61.53, CH ₂	15 ^{'''}		164.95/164.78, C
1 ^{'''}	4.25 (d, 7.7) ^b	105.01/104.88, CH	5-OH	13.58/13.46 (s)	

^{a,b}overlapped with each other for the same superscript; ^coverlapped by solvent.

be eight spinosin derivatives [6^{'''}-dihydrophaseoyl- (**4**),⁵ 6^{'''}-*p*-coumaroyl- (**5**),²⁰ 6^{'''}-feruloyl- (**6**),⁴ 6^{'''}-sinapoyl- (**7**),²⁰ 6^{'''}-(4^{'''}-*O*- β -D-glucopyranosyl)-vanilloyl- (**8**),⁶ 6^{'''}-vanilloyl- (**9**)²¹ spinosin, spinosin (**10**),⁴ and isospinosin (**11**)⁴], two flavone C-glycosides [vicenin-2 (**12**),²² apigenin 6-*C*- α -L-rhamnopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside (**13**),²³], one triterpenoid saponin [jujuboside A (**14**)²⁴], six lignans [pinoresinol-4,4'-di- β -D-glucoside (**15**),²⁵ erythro-dihydroxydehydrodicoumaroyl alcohol (**16**),²⁶ threo-dihydroxydehydrodicoumaroyl alcohol (**17**),²⁶ aegineoside (**18**),²⁷ (+)-dehydrodi-coniferyl alcohol-4-*O*- β -D-glucoside (**19**),²⁸ lariciresinol-4'-*O*- β -D-glucopyranoside (**20**)²⁹], one alkaloid [zizyphusine (**21**)³⁰] and one amino acid [tryptophan (**22**)³¹], by comparison of their spectroscopic data with the reported literature values.

Compound **1** was isolated as a yellow amorphous powder. Its molecular formula was deduced to be C₄₃H₅₀O₁₉ on the basis of HREIMS (m/z 870.2999 [M]⁺). The IR spectrum showed absorption bands at 3430 and 1708 cm⁻¹ due to hydroxyl and carbonyl groups, respectively. The UV spectrum exhibited maximum absorptions at 210, 272, and 332 nm. All the protons and carbons of **1** appeared as pair signals in the ^1H and ^{13}C NMR spectra, which is characteristic of signals arising from a spinosin skeleton⁵. In addition, the remaining 15 carbon resonances were further classified by DEPT experiment as six quaternary carbons, including a ketone (δ_{C} 208.37/208.35, C-4^{'''}) and a carbonyl (δ_{C} 164.95/164.78, C-15^{'''}), three olefinic methines, three methylenes including one oxygen-bearing (δ_{C} 76.66, C-11^{'''}) and three quaternary methyl (δ_{C} 20.72/20.70, 15.35/15.28, 19.15/19.11, C-10^{'''}, C-12^{'''}, C-13^{'''}). The ^1H NMR spectrum displayed the presence of two *trans*-coupled olefinic protons (δ_{H} 6.40/6.39, 7.89/7.81, each 1H, d, J = 15.7 Hz, H-7^{'''}, H-8^{'''}), one singlet olefinic proton at δ_{H} 5.50/5.50 (1H, s, H-14^{'''}) and three methyl singlets [δ_{H} 1.91/1.87, 0.88/0.87, 1.06/1.03 (each 3H, s)]. The aforementioned data of **1** were closely related to those of 6^{'''}-dihydrophaseoylspinosin (**4**). The difference between **1** and **4** was the sesquiterpene moiety, featuring with an additional ketone in **1**, relative to the oxygen-bearing methine in **4**. In the HMBC spectrum of **1** (Figure 2), correlations of both H-3^{'''} (δ_{H} 2.61/2.27) and H-5^{'''}

(δ_{H} 2.76/2.30) with C-4^{'''} (δ_{C} 208.37/208.35), could assign the additional ketone (δ_{C} 208.37/208.35) to be C-4^{'''}. The above data of the sesquiterpene moiety of **1** was essentially identical to those of phaseic acid.³² The position of the phaseic acid moiety in **1** was revealed to be at C-6^{'''} by the HMBC correlation of the H-6^{'''} (δ_{H} 3.87/3.62) with the carbonyl carbon at δ_{C} 164.95/164.78 (C-15^{'''}). Other HMBC and ^1H - ^1H COSY correlations (Figure 2), with electronic supplementary material further confirmed the structure of **1** as shown in Figure 1.

**Figure 2.** Key HMBC and ROESY correlations of compound **1**

The relative configuration of compound **1** was determined on the basis of the coupling constants and ROESY experiment (Figure 2). The *trans* double bond between C-7^{'''} and C-8^{'''} was deduced due to the large coupling constant (15.7 Hz) of $J_{7''',8'''}^{\text{H}}$, while the *cis* double bond between C-9^{'''} and C-14^{'''} was indicated by the ROESY correlations of the olefinic H-14^{'''} (δ_{H} 5.50/5.50) with Me-10^{'''} (δ_{H} 1.91/1.87). In the ROESY spectrum of **1**, correlations of H-7^{'''} and H-8^{'''} with both Me-12^{'''} and Me-13^{'''} were observed. In addition, the H-3 α ^{'''} and H-3 β ^{'''} were correlated with H-11^{'''} and Me-12^{'''}, respectively. These data revealed that the unsaturated side chain -CH(7)=CH(8)-C(9)=CH(14)-COO(15)- of phaseic acid moiety in **1** oriented to the same side of both Me-12^{'''} and Me-13^{'''}, while the CH₂-11^{'''} and O-C(6^{'''}) were oriented to the opposite side of Me-12^{'''}, Me-13^{'''} and C-7^{'''} side chain. Alkaline hydrolysis of **1** with 0.5% NaOH yielded spinosin (**10**) and phaseic acid (**1a**). Compound **1a** showed the similar NMR spectroscopic data and optical rotation value ($[\alpha]_{\text{D}}^{20}$ -

Table 2. ^1H (600 MHz) and ^{13}C (150 MHz) NMR spectroscopic data of compounds **2** and **3** (DMSO- d_6 ; 313 K; δ in ppm)

position	2		3	
	δ_{H} (J, Hz)	δ_{C}	δ_{H} (J, Hz)	δ_{C}
2		164.10/163.89, C		163.89/163.84, C
3	6.69/6.51 (s)	103.17/102.92, CH	6.70/6.46 (1H, s)	102.89/102.74, CH
4		182.22/181.78, C		182.23/181.69, C
5		160.81/159.46, C		160.70/159.48, C
6		108.76/108.74, C		108.81/108.66, C
7		165.23/163.60, C		165.09/163.56, C
8	6.69/6.69 (s)	90.55/89.88, CH	6.64/6.53 (1H, s)	90.47/89.85, CH
9		157.01/156.85, C		156.91/156.73, C
10		104.45/103.96, C		104.41/103.90, C
1'		121.13/121.09, C		121.02/120.86, C
2',6'	7.80/7.79 (d, 8.8)	128.47/128.39, CH	7.82/7.75 (d, 8.7)	128.46/128.41, CH
3',5'	6.88/6.83 (d, 8.8)	115.76/115.70, CH	6.93/6.92 (d, 8.7)	115.77/115.66, CH
4'		161.23/161.15, C		161.39/161.34, C
7-OCH ₃	3.90/3.87 (s)	56.40/ 56.10, CH ₃	3.87/3.80 (s)	56.37/56.09, CH ₃
1''	4.70/4.69 (d, 9.8)	70.98/ 70.64, CH	4.69/4.68 (d, 9.7)	71.02/70.67, CH
2''	4.49 (t, 9.3)/4.25 (t, 9.3)	81.65/ 80.13, CH	4.45 (t, 9.4)/4.23 (t, 9.4)	81.59/80.26, CH
3''	3.44 (m)	78.81/78.63, CH	3.43 ^a	78.49, CH
4''	3.16 ^a	70.33/70.27, CH	3.16 ^a	70.33/70.27, CH
5''	3.16 ^a	81.93, CH	3.16 ^a	81.91/81.90, CH
6''	3.82 ^b /3.38 (m)	61.53/61.49, CH ₂	3.70 (1H, m)/3.37 ^a	61.52/61.48, CH ₂
1'''	4.31/4.30 (d, 7.3)	105.76/105.70, CH	4.28/4.27 (d, 7.8)	105.61/105.16, CH
2'''	2.93 (t, 8.3)/2.90 (t, 8.3)	74.41/74.38, CH	2.94 (t, 8.1)/2.89 (t, 8.1)	74.54/74.51, CH
3'''	3.11 (m)	76.31, CH	3.11 ^c	76.15/76.11, CH
4'''	3.09 (m)	68.86/68.51, CH	3.08 ^c	68.96/68.84, CH
5'''	2.98 (m)	73.25/72.94, CH	2.97 (1H, m)	73.15, CH
6'''	4.05/3.65 (m)	62.41/62.29, CH ₂	4.04 (1H, m)/3.61 (1H, m)	62.74/62.21, CH ₂
1''''		129.46/129.21, C		122.93/122.80, C
2''''	6.86/6.69 (s)	105.53/105.18, CH	7.61/7.49 (d, 8.7)	130.83/130.64, CH
3''''		152.98/152.87, C	7.04/6.95 (d, 8.8)	115.88/115.86, CH
4''''		139.43/139.38, C		161.00/160.95, C
5''''		152.98/152.87, C	7.04/6.95 (d, 8.8)	115.88/115.86, CH
6''''	6.86/6.69 (s)	105.53/105.18, CH	7.61/7.49 (d, 8.7)	130.83/130.64, CH
7''''	7.22/7.06 (d, 15.8)	144.32/144.15, CH		164.74/164.65, C
8''''	6.40/6.30 (d, 15.8)	116.80/116.29, CH		
9''''		166.08/165.96, C		
3''''-OCH ₃	3.82/3.79 (s) ^b	55.98/55.90, CH ₃		100.03/ 99.91, CH
4''''-OCH ₃	3.71/3.70 (s)	60.08/60.06, CH ₃		73.18, CH
5''''-OCH ₃	3.82/3.79 (s) ^b	55.98/55.90, CH ₃		77.15/76.59, CH
1'''''			5.00/4.96 (d, 7.5)	69.71/69.68, CH
2'''''			3.28 ^a	78.77/78.79, CH
3'''''			3.34 ^a	60.69/60.67, CH ₂
4'''''			3.18 ^a	
5'''''			3.44 ^a	
6'''''			3.70 (1H, m)/3.50 ^a	
5-OH	13.59 (s)		13.64 (s)	

^aoverlapped by solvent; ^boverlapped with each other.

21.7, *c* 0.098, MeOH) with those of the reported (–)-phaseic acid ($[\alpha]_{\text{D}}^{16} - 18.0$, *c* 0.10, MeOH).^{32,33} Therefore, the structure of compound **1** was deduced as shown in Figure 1 and named 6''-(–)-phaseoylspinosin.

Compound **2**, a yellow amorphous powder, has a molecular formula determined to be C₄₀H₄₄O₁₉, as deduced from the HREIMS (*m/z* 828.2475, calcd. for 828.2477). The ^1H and ^{13}C NMR spectra of **2** exhibited the characteristic features of a spinosin skeleton. In addition, a set of signals arising from one carbonyl (δ_{C} 166.08/165.96, C-9'''''), three methoxyl [δ_{C} 55.98/55.90 (OCH₃ × 2), 60.08/60.06], four olefinic methines [δ_{C} 105.53/105.18 (CH × 2), 144.32/144.15 (CH), 116.80/116.29 (CH)], and four aromatic quaternary carbons [δ_{C} 129.46/129.21 (C), 152.98/152.87 (C × 2), 139.43/139.38 (C)] were observed in the ^{13}C NMR (DEPT) spectra. The ^1H NMR spectrum displayed the existence of a symmetric 1,3,4,5-tetra-substituted aromatic ring [δ_{H} 6.86/6.69 (2H, s)], one *trans* double bond [δ_{H} 7.22/7.06, 6.40/6.30 (each 1H, d, *J* = 15.8 Hz, H-7''''', H-8''''')] and three methoxyl groups [δ_{H} 3.82/3.79 (6H, s, 3''''', 5'''''-OMe); δ_{H} 3.71/3.70 (3H, s, 4'''''-OMe)]. The aforementioned data suggested that **2** was a

spinosin derivative acylated with a 3,4,5-trimethoxy-(*E*)-cinnamoyl moiety.³⁴ In the HMBC spectrum of **2** (Figure 3), correlations between the H-6'''' (δ_{H} 4.05/3.65) and C-9'''' (δ_{C} 166.08/165.96) indicated the linkage of the cinnamoyl moiety with C-6'''' (δ_{C} 62.41/62.29) of spinosin unit. Other HMBC correlations (Figure 3) were used to further confirm the structure of **2** as shown in Figure 1. Thus, the structure of compound **2** was determined as 6''''-(3''''',4''''',5'''''-trimethoxy)-(E)-cinnamoylspinosin.

Compound **3** was isolated as a yellow amorphous powder. On the basis of the HREIMS (*m/z* 890.2523, calcd. for




Figure 3. Key HMBC (H→C) correlations of compound **2**

890.2481), its molecular formula was determined to be $C_{41}H_{46}O_{22}$. The 1H and ^{13}C NMR spectra also showed the presence of a spinosin skeleton in **3**. In addition, an AA'BB' coupled aromatic system [δ_H 7.61/7.49 (2H, d, $J = 8.7$ Hz, H-2''', 6''') and δ_H 7.04/6.95 (2H, d, $J = 8.8$ Hz, H-3''', 5''')] was observed in the 1H NMR spectrum, together with an additional anomeric proton at δ_H 5.00/4.96 (1H, d, $J = 7.5$ Hz). The ^{13}C NMR (DEPT) spectra showed the occurrence of a carboxyl (δ_C 164.74/164.65, C-7''') and six aromatic carbons arising from a benzoyl unit, and six oxygen-bearing aliphatic carbons due to a glucosyl moiety. The above data revealed that compound **3** was an analogue of **8**,⁶ except for the absence of one methoxyl group associated with the benzoyl moiety, related to **8**. The HMBC correlations of the anomeric proton at H-1'''' (δ_H 5.00/4.96) with C-4'''' (δ_C 161.00/160.95), H-2''', 6'''' (δ_H 7.61/7.49) with C-4'''' (δ_C 161.00/160.95) and C-7'''' (164.74/164.65), and H-3''', 5'''' (δ_H 7.04/6.95) with C-1'''' (δ_C 122.93/122.80) suggested the additional glucosyl unit was connected to the benzoyl C-4'''' position. The linkage of the benzoyl group with C-6''' of spinosin moiety were supported by the HMBC correlations from H-6''' (δ_H 4.04/3.61) to C-7'''' (δ_C 164.74/164.65). Consequently, the structure of compound **3** was determined to be 6'''-(4''''-*O*- β -D-glucopyranosyl)-benzoylspinosin.

It is note that the 1H and ^{13}C NMR data of the spinosin (**10**) and its derivatives **1–9** exhibited doubling of signals at room temperature due to the rotational isomers produced by the rotational barriers 7-OCH₃ in flavones-6-C-glycoside.⁴

As compared with the positive control, tacrine (59.0%), compounds **1**, **2**, **4**, **7** and **14** displayed moderate AChE inhibitory activity with inhibition values of 24.9%, 33.9%, 26.9%, 28.8% and 46.2%, respectively, at a concentration of 1 μ M, by the spectrophotometric method developed by Ellman et al.³⁵ with slight modification. Interestingly, AChE inhibition of compound **8** was only 7.8% at 1 μ M concentration.

Experimental Section

General Experimental Procedures. Optical rotations were determined with a Jasco P-1020 polarimeter. UV (in MeOH) spectra were obtained with the Shimadzu UV-2401 PC spectrophotometer. The Bruker Tensor-27 infrared spectrophotometer was used for IR spectra as KBr pellets. ESIMS and HREIMS spectra were recorded on API QSTAR Pulsar spectrometer and Waters Autospec Premier P776, respectively. 1D and 2D NMR spectra were performed on Bruker Avance III-600MHz spectrometers with TMS as an internal standard. Semi-preparative and preparative HPLC studies were performed on an Agilent 1260 and Gilson GX-27X liquid chromatograph. TLC was performed on precoated TLC plates (0.2–0.25 mm thickness, GF254 Si gel 60, Qingdao Marine Chemical Co., Ltd.) with compounds visualized by spraying the dried plates with 10% aqueous H₂SO₄ followed by heating until the plate was dry. Silical gel (200–300 mesh, Qingdao Marine Chemical Co., Ltd.), Diaion HP20SS (Mitsubishi Chemical Co., Ltd.), Lichroprep RP-18 (40–63 μ m, Merck), Sephadex LH-20 (25–100 μ m, Pharmacia Fine Chemical Co., Ltd.), Chromatorex ODS (100–200 mesh, Fuji Silysia Chemical Co., Ltd.), Toyopearl HW40C (50–100 μ m, Tosoh Co., Ltd.) and MCI-gel CHP20P (75–150 μ m, Mitsubishi Chemical Co., Ltd.) were used for column chromatography (CC). The chemicals used for bioassay

including *S*-acetylthiocholine iodide, *S*-butyrylthiocholine iodide, 5,5'-dithio-bis-(2-nitro-benzoic) acid (DTNB), and AChE was derived from human erythrocytes purchased from Sigma Chemicals.

Plant Material. The seeds of *Z. mauritiana* were collected from the herbal medicine market in Kunming, Yunnan Province, China, in July, 2011, and identified by Prof. Chong-Ren Yang (Kunming Institute of Botany, Chinese Academy of Sciences). A voucher sample (KIB-Z-00331) has been deposited in the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences.

Extraction and Isolation. The air-dried seeds (20 kg) of *Z. mauritiana* were powdered, and extracted three times per 2 hours with MeOH at 60 °C. The extracts was suspended in H₂O and degreased by petroleum ether. The H₂O-soluble layer (1.2 kg) was applied to a Diaion HP20SS column, eluting with H₂O/MeOH (1:0→0:1), to give fractions I–IV. Compound **10** (13.6 g) was obtained by crystallization from fraction III, and the remaining part was further subjected to Sephadex LH-20 chromatography column, eluting with MeOH-H₂O (10:90, 30:70, 50:50, 70:30 and 100:0) to derive the subfractions (III-1 and III-2). Subfraction III-1 (20.5 g) was subjected to Chromatorex ODS column, and eluted with H₂O/MeOH (1:0→0:1), to derive seven fractions (III-1-1–7). Fraction III-1-3 (2.0 g) was subjected to Sephadex LH-20, MCI-gel, RP-18, silica gel and semi-preparative HPLC, and obtained compounds **12** (7 mg), **13** (8 mg), **16** (4 mg), **17** (5 mg), **18** (31 mg) and **22** (26 mg). Fraction III-1-4 (5.0 g) was successively separated by Toyopearl HW40C, Sephadex LH-20, silica gel and Sephadex LH-20, then compound **3** (40 mg), **11** (40 mg), **19** (69 mg) and **20** (63 mg) were obtained. Compound **8** (10 mg) was obtained from Fr. III-1-6 (1.1 g) by repeated CC over Toyopearl HW40C, MCI, RP-18 and finally purified by HPLC using MeCN-H₂O (18:82) as elution. The sub-fraction III-1-7 (3.2 g) was successively subjected to Toyopearl HW40C, MCI-gel, Sephadex LH-20, and silica gel to afford compounds **1** (139 mg), **4** (170 mg), **7** (113 mg) and **15** (47 mg). Furthermore, fraction III-2 (12.6 g) was successively separated by Rp-18, Toyopearl HW40C and preparative HPLC using MeCN-H₂O, and purified by semi-preparative HPLC using MeCN-H₂O, and isolate compound **9** (4 mg). Similarly, Fraction IV was subjected to Sephadex LH-20 chromatography column, and eluted with MeOH-H₂O (30:70, 50:50, 70:30 and 90:10) and was successively separated by Toyopearl HW40C, Rp-18, silica gel, Sephadex LH-20, MCI-gel and silica gel were used to isolate compounds **2** (280 mg), **5** (11 mg), **6** (200 mg), **14** (137 mg) and **21** (109 mg).

6'''-(–)-Phaseoylspinosin (1): yellow amorphous powder; $[\alpha]_D^{20} - 31.7$ (c 0.2, MeOH); UV (MeOH) λ_{max} (log ϵ) 332 (4.31), 272 (4.59) and 210 (4.56) nm; IR (KBr) ν_{max} 3430, 2928, 2883, 1708, 1653, 1607, 1511, 1491, 1448, 839 and 779 cm^{-1} ; 1H and ^{13}C NMR data see Table 1; ESIMS m/z 893 [$M + Na$]⁺; HREIMS m/z 870.2999 (calcd. for $C_{43}H_{50}O_{19}$ [M]⁺, 870.2946).

6'''-(3''''',4''''',5'''''-Trimethoxy)-cinnamoylspinosin (2): yellow amorphous powder; $[\alpha]_{\text{D}}^{19} - 63.4$ (c 0.2, MeOH); UV (MeOH) λ_{max} (log ϵ) 309 (4.52) and 206 (4.65) nm; IR (KBr) ν_{max} 3411, 2938, 1706, 1654, 1607, 1508, 1491, 1450, 836 and 778 cm^{-1} ; ^1H and ^{13}C NMR data see Table 2; ESIMS m/z 851 $[\text{M} + \text{Na}]^+$; HREIMS m/z 828.2475 (calcd. for $\text{C}_{40}\text{H}_{44}\text{O}_{19} [\text{M}]^+$, 828.2477).

6'''-(4'''''-O- β -D-Glucopyranosyl)-benzoylspinosin (3): yellow amorphous powder; $[\alpha]_{\text{D}}^{19} - 83.2$ (c 0.2, MeOH); UV (MeOH) λ_{max} (log ϵ) 333 (4.31), 307 (4.25), 251 (4.42) and 204 (4.68) nm; IR (KBr) ν_{max} 3423, 2919, 1704, 1653, 1608, 1510, 1491, 1449, 839 and 770 cm^{-1} ; ^1H and ^{13}C NMR data see Table 2; ESIMS m/z 913 $[\text{M} + \text{Na}]^+$; HREIMS m/z 890.2523 (calcd. for $\text{C}_{41}\text{H}_{46}\text{O}_{22} [\text{M}]^+$, 890.2481).

Alkaline Hydrolysis of 1–3. A solution of compound **1** (50 mg) in 0.5% NaOH (2 mL) was stirred at 65 °C for 1 h. The reaction mixture was partitioned with H_2O and n -BuOH, successively. Further CC over Sephadex LH-20 to afford spinosin (20 mg) from the n -BuOH layer. The water layer was neutralized with 0.5 N HCl solution and extracted with CHCl_3 . The organic layer was subjected to preparative TLC over silica gel (CHCl_3 -MeOH, 20:1) to afford (–)-phaseic acid (**1a**, 1.9 mg): white amorphous powder; $[\alpha]_{\text{D}}^{20} - 21.7$ (c 0.098, MeOH); ESIMS m/z 303 $[\text{M} + \text{Na}]^+$; ^1H NMR (600 MHz, DMSO- d_6): δ_{H} 0.87 (3H, s, H-12), 1.07 (3H, s, H-13), 1.97 (3H, s, H-10), 2.29 (1H, d, $J = 17.6$ Hz, H-3a), 2.50 (1H, overlapped with solvent, H-5a), 2.67 (1H, d, $J = 17.6$ Hz, H-3b), 2.78 (1H, d, $J = 17.4$ Hz, H-5b), 3.51 (1H, d, $J = 7.4$ Hz, H-11a), 3.75 (1H, d, $J = 7.4$ Hz, H-11b), 5.70 (1H, s, H-14), 6.35 (1H, d, $J = 15.6$ Hz, H-7), 8.02 (1H, s, $J = 15.6$ Hz, H-8). ^{13}C NMR (150 MHz, DMSO- d_6): δ_{C} 15.49 (C-12), 19.30 (C-13), 20.91 (C-10), 48.31 (C-2), 52.04 (C-3), 53.13 (C-5), 76.71 (C-11), 81.35 (C-1), 86.14 (C-6), 121.34 (C-14), 131.14 (C-8), 132.26 (C-7), 150.8 (C-9), 168.3 (C-15), 208.71 (C-4)]. TLC analysis also indicated the presence of spinosin in the aqueous layer (CHCl_3 -MeOH- H_2O 8:2:0.2, R_f 0.23). Similarly to **1**, alkaline hydrolysis of **2** and **3** (each 10 mg) was carried out, separately. The existence of spinosin was confirmed by TLC analysis (CHCl_3 -MeOH- H_2O 8:2:0.2, R_f 0.23).

Acid Hydrolysis of 1–3. Compounds **1–3** (each 10 mg) was dissolved in 2 N HCl (2 mL) and refluxed at 80 °C for 10 h. The reaction mixture was neutralized with Amberlit IRA-401 and a sugar residue was obtained. Identification of D-glucose was performed by comparison of OD (+) with authentic samples.

Acetylcholinesterase (AChE) Inhibitory Activity. The AChE inhibitory activity was assayed using the spectrophotometric method developed by Ellman et al.³⁴ with slightly modification. In brief, the reaction mixture (200 μL in total) containing phosphate buffer (pH 8.0), testing compound (50 μM in DMSO), and AChE (0.02 U/mL), was incubated for 20 min (30 °C). Then, the reaction was initiated by the addition of 40 μL of solution containing DTNB (0.625 mM) and acetylthiocholine iodide (0.625 mM). The hydrolysis of acetylthiocholine was monitored at 405 nm every 30 seconds for one hour. Tacrine was used as positive control with final

concentration of 0.333 μM . All the reactions were performed in triplicate. The percentage inhibition was calculated as follows:

$$\% \text{ inhibition} = (\text{E} - \text{S}) / \text{E} \times 100$$

(E is the activity of the enzyme without test compound and S is the activity of enzyme with the test compound).

Electronic Supplementary Material

Supplementary material is available in the online version of this article at <http://dx.doi.org/10.1007/s13659-013-0028-5> and is accessible for authorized users.

Acknowledgments

We are grateful to the members of the analytical group of our institute for the measurement of spectroscopic data. The authors are sincerely grateful to Prof. Huai-Rong Luo for the AChE inhibitory activity bioassay. This work was supported by the 973 Program of Science and Technology of China (2011CB915503) and the Fourteenth Candidates of the Young Academic Leaders of Yunnan Province (Min Xu, 2011CI044).

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

- [1] Ji, C. J.; Zeng, G. Z.; Han, J.; He, W. J.; Zhang, Y. M.; Tan, N. H. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 6377–6380.
- [2] Chen, Y. L.; Zhou, B. K. *In Chinese Flora*; Science Press: Beijing, 1982; Vol. 48, pp 131–146
- [3] Liu, M. J. *Acta Hort. Sin.* **1999**, *26*, 302–308.
- [4] Cheng, G.; Bai, Y. J.; Zhao, Y. Y.; Tao, J.; Liu, Y.; Tu, G. Z.; Ma, L. B.; Liao, N.; Xu, X. J. *Tetrahedron* **2000**, *56*, 8915–8920.
- [5] Zhang, L.; Xu, Z. L.; Wu, C. F.; Yang, J. Y.; Kano, Y.; Yuan, D. J. *Asian. Nat. Prod. Res.* **2012**, *14*, 121–128.
- [6] Xie, Y. Y.; Xu, Z. L.; Wang, H.; Kano, Y.; Yuan, D. J. *Asian. Nat. Prod. Res.* **2011**, *13*, 1151–1157.
- [7] Tan, N. H.; Zhou, J. *Chem. Rev.* **2006**, *106*, 840–895.
- [8] Tschesche, R.; Wilhelm, H.; Fehlhaber, H. W. *Tetrahedron Lett.* **1972**, *26*, 2609–2612.
- [9] Tschesche, R.; Wilhelm, H.; Kaufmann, E. U.; Eckhardt, G. *Justus Liebigs Ann. Chem.* **1974**, 1694–1701.
- [10] Tschesche, R.; Hillebrand, D.; Wilhelm, H.; Ammermann, E.; Eckhardt, G. *Phytochemistry* **1977**, *16*, 1025–1028.
- [11] Jossang, A.; Zahir, A.; Diakite, D. *Phytochemistry* **1996**, *42*, 565–567.
- [12] Panseeta, P.; Lomchoey, K.; Prabpai, S.; Kongsaree, P.; Sukasamrarn, A.; Ruchiraeat, S.; Suksamrarn, S. *Phytochemistry* **2011**, *72*, 909–915.
- [13] Srivastava, S. K.; Srivastava, S. D. *Phytochemistry* **1979**, *18*, 1758–1759.
- [14] Agarwal, S. K.; Singh, S. S.; Verma, S.; Kumar, S. *Indian J. Chem. B: Org. Chem. Incl. Med. Chem.* **2000**, *39*, 872–874.
- [15] Krasutsky, P. A. *Nat. Prod. Rep.* **2006**, *23*, 919–942.
- [16] Lee, S. S.; Chen, W. C.; Huang, C. F.; Su, Y. J. *Nat. Prod.* **1998**, *61*, 1343–1347.
- [17] Lv, T.; Xu, M.; Wang, D.; Zhu, H. T.; Yang, C. R.; Zhang, T. T.; Zhang, Y. J. *Nat. Prod. Bioprospect.* **2012**, *2*, 217–221.
- [18] Xu, M.; Wang, D.; Zhang, Y. J.; Yang, C. R. *J. Nat. Prod.* **2007**, *70*, 880–883.
- [19] Xu, M.; Zhang, M.; Zhang, Y. J.; Yang, C. R. *Helv. Chim. Acta.*

- 2009, 92, 321–327.
- [20] Tanaka, Y.; Sanada, S. *Shoyakugaku Zasshi*. **1991**, 45, 148–152.
- [21] Wu, Y.; He, F.; Pan, Q.; Shi, Y.; Min, Z. D.; Liang, J. Y. *Chem. Nat. Compd.* **2011**, 47, 369–372.
- [22] Xie, C.; Veitch, N. C.; Houghton, P. J.; Simmonds, M. S. J. *Chem. Pharm. Bull.* **2003**, 51, 1204–1207.
- [23] Kitajima, J.; Kimizuka, K.; Arai, M.; Tanaka, Y. *Chem. Pharm. Bull.* **1998**, 46, 1647–1649.
- [24] Renault, J. H.; Ghedira, K.; Thepenier, P.; Lavaud, C.; Zeches-Hanrot, M.; Men-Olivier, L. L. *Phytochemistry* **1997**, 44, 1321–1327.
- [25] Schumacher, B.; Scholle, S.; Holzl, J.; Khudeir, N.; Hess, S.; Muller, C. E. *J. Nat. Prod.* **2002**, 65, 1479–1485.
- [26] Deyama, T.; Ikawa, T.; Kitagawa, S.; Nishibe, S. *Chem. Pharm. Bull.* **1987**, 35, 1785–1789.
- [27] Ho, J. C.; Chen, C. M.; Row, L. C. *J. Chin. Chem. Soc.* **2003**, 50, 1271–1274.
- [28] Wang, C. Z.; Jia, Z. J. *Phytochemistry* **1997**, 45, 159–166.
- [29] Masataka, S.; Masao, K. *Heterocycles* **1993**, 36, 117–121.
- [30] Han, B. H.; Park, M. H.; Han, Y. N. *Arch. Pharm. Res.* **1989**, 12, 263–268.
- [31] Aldrich. *Library of 13C and 1H FT NMR Spectra*. **1992**, 3, 143.
- [32] Hirai, N.; Kondo, S.; Ohigashi, H. *Biosci. Biotechnol. Biochem.* **2003**, 67, 2408–2415.
- [33] Kitahara, T.; Touhara, K.; Watanabe, H.; Mori, K. *Tetrahedron* **1989**, 45, 6387–6400.
- [34] Payo-Hill, A. L.; Domingueza, R. S.; Suarez, M. O.; Batista-Baeza, M.; Castro Velez, H. T.; Rastrelli, L.; Aquinoc, R. *Phytochemistry* **2000**, 54, 927–932.
- [35] Ellman, G. L.; Courtney, K. D.; Andres, V. J.; Featherstone, R. M. *Biochem Pharmacol.* **1961**, 7, 88–95.